Market Research Logo

Global Immunotherapy Drugs 2016-2020

Global Immunotherapy Drugs 2016-2020

About Immunotherapy Drugs

Immunotherapy enhances the innate powers of the immune system. The properties of the immune system to fight abnormal cells give immunotherapy drugs the chance of successfully fighting diseases such as cancer, respiratory, infectious, and autoimmune disorders.

Technavio’s analysts forecast the global immunotherapy drugs market to grow at a CAGR of 11.52% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global immunotherapy drugs market for the period 2015-2020. To calculate the market size, the report considers revenue generated from the sales of immunotherapy drugs used to treat cancer, respiratory, infectious, autoimmune, and inflammatory diseases. It also considers the revenues to be generated from the sales of drugs, which are expected to be launched into the market, along with the decline in revenues from the patent expiries of marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Immunotherapy Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company (BMS)
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson Private Ltd.
  • Merck & Co. Inc.
Other prominent vendors
  • AB Science
  • Ablynx
  • Acorda Therapeutics
  • ADC Therapeutics
  • Aduro Biotech
  • Advantagene
  • Advaxis
  • Agensys Inc.
  • Agenus Inc.
  • Alder Biopharmaceuticals
  • AlphaVax
  • Altor BioScience
  • Antares Pharma
  • Antigen Express
  • Argos Therapeutics Inc.
  • Astellas Pharma
  • AstraZeneca
  • AVAX Technologies
  • Bavarian Nordic
  • Baxter
  • Bayer
  • Biogen
  • Biotech Pharmaceutical
  • Biothera
  • Boehringer Ingelheim
  • Can-Fite BioPharma
  • Celgene
  • Celldex Therapeutics
  • Celltrion
  • Cel-Sci
  • ChemoCentryx
  • Chugai Pharmaceutical
  • Coherus BioSciences
  • CTI BioPharma
  • CureVac
  • Cytos Biotachnology
  • Daiichi Sankyo
  • Eisai
  • Eli Lilly
  • Fortress Biotech
  • Galena Biopharma
  • Genexine
  • Genmab
  • Gilead Sciences
  • GSK
  • GlobeImmune
  • Gradalis
  • Heat Biologics
  • Hospira
  • Idera
  • Immatics
  • ImmunoCellular Therapeutics
  • Immunomedics
  • ImmuPharma
  • Immutep
  • Incyte
  • Inovio Pharmaceuticals
  • Intas Pharmaceuticals
  • Invion
  • ISA Pharmaceuticals
  • Janssen Biotech
  • Juvaris Biotherapeutics
  • KaloBios Pharmaceuticals
  • Kyowa Hakko Kirin
  • Lexicon Pharmaceuticals
  • MedImmune
  • Morphotek
  • Neovii Biotech
  • Northwest Biotherapeutics
  • Novartis
  • NovaRx
  • Novo Nordisk
  • OncoMed Pharmaceuticals
  • Oncothyreon
  • Oncovir Inc.
  • Opexa Therapeutics Inc.
  • Oxford BioMedica
  • Pfizer
  • Prima BioMed
  • Principia
  • Progenics
  • Provectus Biopharmaceuticals
  • Regeneron
  • Sandoz
  • Sanofi
  • Santarus
  • Seattle Genetics
  • Sotio
  • Spectrum Pharmaceuticals
  • Takeda
  • TG Therapeutics
  • Transgene
  • UbiVac
  • UCB
  • Vaccinex
  • Vaccinogen
  • Vaxon Biotech
  • Vertex Pharmaceuticals
  • Vical
  • Vitae Pharmaceuticals
  • XBiotech
Market driver
  • Growing prevalence of cancer and autoimmune diseases
  • For a full, detailed list, view our report
Market challenge
  • Patent expiries of top-selling drugs
  • For a full, detailed list, view our report
Market trend
  • Increase in awareness programs
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Immunotherapy Drugs Market 2016-2020

Technavio recognizes the following companies as the key players in the Global Immunotherapy Drugs Market: AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company (BMS), F. Hoffmann-La Roche AG, Johnson & Johnson Private Ltd., and Merck & Co. Inc.

Other Prominent Vendors in the market are: AB Science, Ablynx, Acorda Therapeutics, ADC Therapeutics, Aduro Biotech, Advantagene, Advaxis, Agensys Inc., Agenus Inc., Alder Biopharmaceuticals, AlphaVax, Altor BioScience, Antares Pharma, Antigen Express, Argos Therapeutics Inc., Astellas Pharma, AstraZeneca, AVAX Technologies, Bavarian Nordic, Baxter, Bayer, Biogen, Biotech Pharmaceutical, Biothera, Boehringer Ingelheim, Can-Fite BioPharma, Celgene, Celldex Therapeutics, Celltrion, Cel-Sci, ChemoCentryx, Chugai Pharmaceutical, Coherus BioSciences, CTI BioPharma, CureVac, Cytos Biotachnology, Daiichi Sankyo, Eisai, Eli Lilly, Fortress Biotech, Galena Biopharma, Genexine, Genmab, Gilead Sciences, GSK, GlobeImmune, Gradalis, Heat Biologics, Hospira, Idera, Immatics, ImmunoCellular Therapeutics, Immunomedics, ImmuPharma, Immutep, Incyte, Inovio Pharmaceuticals, Intas Pharmaceuticals, Invion, ISA Pharmaceuticals, Janssen Biotech, Juvaris Biotherapeutics, KaloBios Pharmaceuticals, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, MedImmune, Morphotek, Neovii Biotech, Northwest Biotherapeutics, Novartis, NovaRx, Novo Nordisk, OncoMed Pharmaceuticals, Oncothyreon, Oncovir Inc., Opexa Therapeutics Inc., Oxford BioMedica, Pfizer, Prima BioMed, Principia, Progenics, Provectus Biopharmaceuticals, Regeneron, Sandoz, Sanofi, Santarus, Seattle Genetics, Sotio, Spectrum Pharmaceuticals, Takeda, TG Therapeutics, Transgene, UbiVac, UCB, Vaccinex, Vaccinogen, Vaxon Biotech, Vertex Pharmaceuticals, Vical, Vitae Pharmaceuticals, and XBiotech.

Commenting on the report, an analyst from Technavio’s team said: “The rising prevalence of cancer and autoimmune diseases has led to innovations and technological advancements, which have helped develop immunotherapy drugs that are more effective than available drugs.”

According to the report, the rising prevalence of cancer and autoimmune diseases has led to innovations and technological advancements, which have helped develop immunotherapy drugs that are more effective than available drugs.

Further, the report states that the patent expiries of branded drugs may hamper the market as this results in the entry of biosimilars, which are less expensive.

Companies Mentioned

AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company (BMS), F. Hoffmann-La Roche AG, Johnson & Johnson Private Ltd., Merck & Co. Inc, AB Science, Ablynx, Acorda Therapeutics, ADC Therapeutics, Aduro Biotech, Advantagene, Advaxis, Agensys Inc., Agenus Inc., Alder Biopharmaceuticals, AlphaVax, Altor BioScience, Antares Pharma, Antigen Express, Argos Therapeutics Inc., Astellas Pharma, AstraZeneca, AVAX Technologies, Bavarian Nordic, Baxter, Bayer, Biogen, Biotech Pharmaceutical, Biothera, Boehringer Ingelheim, Can-Fite BioPharma, Celgene, Celldex Therapeutics, Celltrion, Cel-Sci, ChemoCentryx, Chugai Pharmaceutical, Coherus BioSciences, CTI BioPharma, CureVac, Cytos Biotachnology, Daiichi Sankyo, Eisai, Eli Lilly, Fortress Biotech, Galena Biopharma, Genexine, Genmab, Gilead Sciences, GSK, GlobeImmune, Gradalis, Heat Biologics, Hospira, Idera, Immatics, ImmunoCellular Therapeutics, Immunomedics, ImmuPharma, Immutep, Incyte, Inovio Pharmaceuticals, Intas Pharmaceuticals, Invion, ISA Pharmaceuticals, Janssen Biotech, Juvaris Biotherapeutics, KaloBios Pharmaceuticals, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, MedImmune, Morphotek, Neovii Biotech, Northwest Biotherapeutics, Novartis, NovaRx, Novo Nordisk, OncoMed Pharmaceuticals, Oncothyreon, Oncovir Inc., Opexa Therapeutics Inc., Oxford BioMedica, Pfizer, Prima BioMed, Principia, Progenics, Provectus Biopharmaceuticals, Regeneron, Sandoz, Sanofi, Santarus, Seattle Genetics, Sotio, Spectrum Pharmaceuticals, Takeda, TG Therapeutics, Transgene, UbiVac, UCB, Vaccinex, Vaccinogen, Vaxon Biotech, Vertex Pharmaceuticals, Vical, Vitae Pharmaceuticals, XBiotech.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
    • Assumptions
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Overview: Immunotherapy
    • Types of immunotherapy
      • Table Types of immunotherapy
    • Key events
      • Table Key events in discovery and approvals of immunotherapy drugs
      • Table Immunotherapy drugs approved by US FDA in 2015
    • Reimbursement policies
    • Orphan drug designation and regulatory approvals
      • Table US FDA orphan drug designations and approvals list for immunotherapy drugs
      • Table EU orphan drug designations and approvals list for immunotherapy drugs
  • Pipeline portfolio
    • Table Phase III pipeline molecules for mAbs
    • Table Phase II pipeline molecules for mAbs
    • Table Phase I pipeline molecules for mAbs
    • Table Pipeline molecules for immune checkpoint inhibitors
    • Table Phase III pipeline molecules for vaccines
    • Table Phase II pipeline molecules for vaccines
    • Table Phase I pipeline molecules for vaccines
    • Anticipated number of immuno-oncology pipeline assets with single and multiple indications by 2020
      • Table Near-launch immuno-oncology pipeline assets
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global immunotherapy drugs market 2015-2020 ($ billions)
      • Table Factors influencing global immunotherapy drugs market
      • Table Challenges faced by US immunologists while prescribing immunotherapy drugs 2015
      • Table SWOT analysis of global immunotherapy drugs market
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by type of immunotherapy
    • Table Market segmentation by type of immunotherapy drug
    • mAbs
      • Table Timeline of mAbs approval for cancer by US FDA
      • Table Timeline of mAbs approval for autoimmune, respiratory, and ophthalmic diseases by US FDA
      • Table Global mAbs market 2015-2020 ($ billions)
      • Table Key drivers and challenges of global monoclonal antibodies drugs market
      • Table Top vendor offerings in global mAbs market
    • Immune checkpoint inhibitors
      • Table Global immune checkpoint inhibitors market 2015-2020 ($ billions)
      • Table Key driver and challenge for global immune checkpoint inhibitors market
      • Table Top vendor offerings in global immune checkpoint inhibitors market
    • Vaccines
      • Table Global vaccines market 2015-2020 ($ billions)
      • Table Segmentation of global vaccines market by application 2015
      • Table Key drivers and challenges of global vaccines market
      • Table Top vendor offerings in global vaccines market
    • Non-specific immunotherapies
      • Table Global non-specific immunotherapies market 2015-2020 ($ billions)
      • Table Key drivers and challenges of global non-specific immunotherapies market
      • Table Top vendor offerings in global non-specific immunotherapies market
      • Table Segmentation of global immunotherapy drugs market by type of immunotherapy 2015
      • Table Global immunotherapy drugs market; YoY revenue and growth rate based on type of immunotherapy 2015-2020 ($ billions)
  • Market segmentation by therapy area
    • Table Global immunotherapy drugs market segmentation by therapy area
    • Table Segmentation of global immunotherapy drugs market by therapy area 2015
  • Geographical segmentation
    • Global immunotherapy drugs market by geographical segmentation 2015-2020
      • Table Segmentation of global immunotherapy drugs market by geography 2015
      • Table Global immunotherapy drugs market revenue by geography 2015-2020 ($ billions)
    • Immunotherapy drugs market in Americas
      • Table Immunotherapy drugs market in Americas 2015-2020 ($ billions)
      • Table Market share in the Americas by type of immunotherapy 2015
    • Immunotherapy drugs market in EMEA
      • Table Immunotherapy drugs market in EMEA 2015-2020 ($ billions)
      • Table Market share in Europe by type of immunotherapy 2015
    • Immunotherapy drugs market in APAC
      • Table Immunotherapy drugs market in APAC 2015-2020 ($ billions)
      • Table Market share in APAC by type of immunotherapy 2015
      • Table Global immunotherapy drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions)
  • Market drivers
    • Growing prevalence of cancer and autoimmune diseases
      • Table Global incidence of cancers 2015 and 2020
    • Rise in older population
      • Table Population aged 60 years and over: World, developed, and developing regions (millions)
    • Increase in demand for mAbs
    • Patient assistance programs
      • Table Patient assistance programs for immunotherapy drugs
    • Promising pipeline
      • Table Some pipeline molecules for immunotherapy drugs
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Patent expiries of top-selling drugs
      • Table Approvals and patent expiries of top-selling immunotherapy drugs
    • High costs of biologicals
      • Table Average annual treatment cost per patient for some immunotherapy drugs 2014 ($ millions)
    • Poor diagnosis and screening
    • Adverse effects
    • Stringent regulations
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Increase in awareness programs
    • Emergence of targeted and combination therapies
      • Table Expected combination regimen launches in immune-oncology 2015-2020
    • Emergence of biosimilars
    • Strategic alliances
    • Expected entry of novel vaccines
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2015
      • Table Market share analysis of top vendors
      • Table Competitive assessment of top 10 immunotherapy drugs 2015 ($ billions)
      • Table YoY sales comparison of top five immunotherapy drugs 2013-2015 ($ billions)
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: Immunotherapy drugs segmentation by revenue 2015
      • Table F. Hoffmann-La Roche: Top-selling immunotherapy drugs 2015
      • Table F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan (oncology and immunology indications) 2013-2015 ($ billions)
      • Table F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan (immunology indications only) 2013-2015 ($ billions)
      • Table F. Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2013-2015 ($ billions)
      • Table F. Hoffmann-La Roche: Actemra/RoActemra geographic segmentation by revenue 2015
      • Table F. Hoffmann-La Roche: MabThera/Rituxan geographic segmentation by revenue 2015
      • Table F. Hoffmann-La Roche: YoY revenue and growth rate of Avastin 2012-2015 ($ billions)
      • Table F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin 2012-2015 ($ billions)
      • Table F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in US 2013-2015 ($ billions)
      • Table F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in EU 2013-2015 ($ billions)
      • Table F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in Japan 2013-2015 ($ millions)
      • Table F. Hoffmann-La Roche: YoY revenue and growth rate of Perjeta 2012-2015 ($ billions)
      • Table F. Hoffmann-La Roche: YOY revenue and growth rate of Kadcyla 2013-2015 ($ billions)
      • Table F. Hoffmann-La Roche: Key takeaways
    • AbbVie
      • Table AbbVie: Immunotherapy drugs segmentation by revenue 2015
      • Table AbbVie: YoY revenue and growth rate of HUMIRA 2013-2015 ($ billions)
      • Table AbbVie: YoY revenue and growth rate of HUMIRA in US 2013-2015 ($ billions)
      • Table AbbVie: YoY revenue and growth rate of HUMIRA in ROW 2013-2015 ($ billions)
      • Table AbbVie: Sales of HUMIRA in major markets 2015
      • Table AbbVie: Key takeaways
    • Johnson & Johnson
      • Table Johnson & Johnson: Key immunotherapy drugs segmentation by revenue 2015
      • Table Johnson & Johnson: Top-selling immunotherapy drugs 2015
      • Table Johnson & Johnson: YoY revenue and growth rate of Remicade 2012-2015 ($ billions)
      • Table Johnson & Johnson: YoY revenue and growth rate of Stelara 2012-2015 ($ billions)
      • Table Johnson & Johnson: YoY revenue and growth rate of Stelara in US 2012-2015 ($ billions)
      • Table Johnson & Johnson: YoY revenue and growth rate of Stelara in ROW 2012-2015 ($ millions)
      • Table Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2012-2015 ($ billions)
      • Table Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria in the US 2012-2015 ($ billions)
      • Table Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria in ROW 2012-2015 ($ billions)
      • Table Johnson & Johnson: Key takeaways
    • Merck
      • Table Merck: Business segmentation by revenue 2015
      • Table Merck: Immunotherapy drugs segmentation by revenue 2015
      • Table Merck: Top-selling immunotherapy drugs 2015
      • Table Merck: YoY revenue and growth rate of Gardasil/Gardasil9 2012-2015 ($ billions)
      • Table Merck: YoY revenue and growth rate of ProQuad/M-M-R II/Varivax 2012-2015 ($ billions)
      • Table Merck: YoY revenue and growth rate of Zostavax 2012-2015 ($ millions)
      • Table Merck: YoY revenue and growth rate of Pneumovax 23 2012-2015 ($ millions)
      • Table Merck: YoY revenue and growth rate of RotaTeq 2012-2015 ($ millions)
      • Table Merck: Key takeaways
    • Amgen
      • Table Amgen: Top-selling immunotherapy drugs 2015
      • Table Amgen: YoY revenue and growth rate of Enbrel in US and Canada 2012-2015 ($ billions)
      • Table Amgen: YoY revenue and growth rate of Enbrel in US 2012-2015 ($ billions)
      • Table Amgen: YoY revenue and growth rate of Enbrel in Canada 2012-2015 ($ millions)
      • Table Amgen: YoY revenue and growth rate generated from net product sales of Xgeva 2012-2015 ($ billions)
      • Table Amgen: YoY revenue and growth rate generated from net product sales of Prolia 2012-2015 ($ billions)
      • Table Amgen: YoY revenue and growth rate of Vectibix in US 2012-2015 ($ millions)
      • Table Amgen: YoY revenue and growth rate of Vectibix in ROW 2012-2015 ($ millions)
      • Table Amgen: Key takeaways
    • BMS
      • Table BMS: Business segmentation by revenue 2015
      • Table BMS: Immunotherapy drugs segmentation by revenue 2015
      • Table BMS: Top-selling immunotherapy drugs 2015
      • Table BMS: YoY revenue and growth rate of Orencia 2012-2015 ($ billions)
      • Table BMS: YoY revenue and growth rate generated from net product sales of Yervoy 2012-2015 ($ billions)
      • Table BMS: YoY revenue and growth rate of Erbitux in US, Canada, and Japan 2012-2015 ($ millions)
      • Table BMS: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report